GlobeNewswire Inc | Jan 5, 2022 04:05PM EST

January 05, 2022

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced managements participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.

An on-demand presentation from the H.C. Wainwright conference will be available through Ensysces Investor Relations website at https://ir.ensysce.com/ beginning January 10, 2022, at 7:00am ET.

The Companys Chief Executive Officer Lynn Kirkpatrick, PhD and Chief Financial Officer Dave Humphrey will be available for one-on-one and small group meetings with investors. To schedule a meeting with Ensysce management, please contact your conference representative or you may also email your request to ENSC@mzgroup.us.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms, the Company is in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysces products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visitwww.ensysce.com.

Ensysce Biosciences Company Contact:Lynn Kirkpatrick, Ph.D.Chief Executive Officer(858) 263-4196

Ensysce Biosciences Investor Relations Contact:Shannon DevineMZ North America Main: 203-741-8811ENSC@mzgroup.us

Source: Ensysce Biosciences Inc.